科兴制药(688136) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 353,559,464.74, a decrease of 1.97% compared to the same period last year[4] - Net profit attributable to shareholders increased by 106.21% to CNY 25,577,232.91, driven by enhanced profitability and effective cost management[4] - The net profit after deducting non-recurring gains and losses rose by 124.40% to CNY 22,603,851.46, with overseas sales increasing by 84.33% year-on-year[4] - Basic earnings per share rose by 107.21% to CNY 0.1293, while diluted earnings per share increased by 105.93% to CNY 0.1285[4] - Net profit for Q1 2025 reached CNY 24,851,106.76, an increase of 116.5% compared to CNY 11,488,257.28 in Q1 2024[15] - The company reported a total comprehensive income of CNY 24,847,574.20 for Q1 2025, significantly higher than CNY 11,875,061.34 in Q1 2024[15] Research and Development - Research and development expenses totaled CNY 41,925,690.39, representing 11.86% of operating revenue, an increase of 2.10 percentage points from the previous year[5] - Research and development expenses for Q1 2025 were CNY 37,206,245.26, compared to CNY 35,207,355.05 in Q1 2024, reflecting a 5.7% increase[14] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3,193,719,244.79, reflecting a 1.00% increase from the end of the previous year[5] - As of March 31, 2025, the total assets of the company amounted to RMB 3,193,719,244.79, an increase from RMB 3,162,234,528.16 as of December 31, 2024[10] - The company's current assets totaled RMB 1,323,937,686.60, compared to RMB 1,287,809,760.09 at the end of 2024, reflecting a growth of approximately 2.8%[11] - Total liabilities as of the end of the reporting period were CNY 1,525,814,854.27, slightly up from CNY 1,522,987,869.66[12] - Total equity attributable to shareholders was CNY 1,664,292,398.75, an increase from CNY 1,634,908,540.58[12] Cash Flow - The net cash flow from operating activities was CNY 25,445,147.64, a significant recovery from a negative cash flow of CNY -6,224,291.11 in the same period last year[4] - The company’s cash flow statement for Q1 2025 indicates ongoing operational stability, with a focus on maintaining liquidity[16] - In Q1 2025, the cash inflow from operating activities was $310,620,690.74, an increase of 6.5% compared to $290,482,200.81 in Q1 2024[18] - The net cash flow from operating activities improved to $25,445,147.64 in Q1 2025, compared to a negative $6,224,291.11 in Q1 2024[18] - Cash inflow from investment activities totaled $348,927,679.48 in Q1 2025, down from $393,452,791.58 in Q1 2024[19] - The net cash flow from investment activities was negative at -$110,336,338.45 in Q1 2025, compared to -$224,084,139.42 in Q1 2024, indicating a reduced outflow[19] - Cash inflow from financing activities increased to $176,879,579.90 in Q1 2025, compared to $113,765,000.00 in Q1 2024[19] - The net cash flow from financing activities was $20,664,324.41 in Q1 2025, up from $16,587,852.26 in Q1 2024[19] - The ending cash and cash equivalents balance for Q1 2025 was $489,420,850.82, compared to $346,870,145.31 in Q1 2024, reflecting a significant increase[19] Shareholder Information - The company reported a total of 8,054 common shareholders at the end of the reporting period[8] - The largest shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., holds 66.01% of the shares[8] - The company reported a total of 1,880,572 shares held by the repurchase special securities account, accounting for 0.94% of total shares[9] Strategic Initiatives - The company continues to deepen its overseas commercialization strategy, contributing to the growth in sales and profitability[7] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[17]